Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neuro-Oncology
•
Medical Oncology
•
Neurology
Do you utilize tumor treating fields in patients with anaplastic Pleomorphic Xanthoastrocytoma PXA III?
Related Questions
Is there a role for intravenous temozolomide in place of oral for the 5-day dosing q 28 days after surgery/XRT+Temozolomide for glioblastoma multiforme?
How do you manage follow up for patient who was diagnosed with pineal gland germinomas with drop metastatic to the spinal cord?
How do you counsel glioblastoma multiforme patients on which types of clinical trials to pursue?
How do you time CSF analysis for suspected CNS lymphoma in patients who are on steroids?
In what circumstances would you consider use of IDH inhibitors in high-grade astrocytomas?
When is the best time to try targeted therapy in adult-type diffuse non-IDH glioma?
Would you consider adding gabapentin off label for use in the treatment of glioblastoma at this time?
How well does a negative non-contrast MRI of the brain exclude metastasis in a patient with squamous cell carcinoma of the lung?
How do different inflammatory markers like CRP and ferritin contribute differently, if at all, to the monitoring of CART neurotoxicity?
What are your top takeaways in Neuro Oncology from ASCO 2025?
